Words matter when it comes to drug importation
As we close out 2017, personal drug importation via online pharmacies remains a viable lifeline for American patients who can’t afford prices at their local pharmacies. Recent FDA actions against pharmacy storefront offices in Florida, ones that help Americans buy more affordable meds internationally, are troubling. On a positive note, a backlash against that crackdown by members of Congress, including Senators Bill Nelson (D-FL), Chuck Grassley (R-IW), and Amy Klobuchar (D-MN) has begun and will certainly grow. But what’s most on my mind is the FDA’s vocabulary about drug importation and how people tend to confuse certain terms.
In its efforts against personal drug importation, the FDA tells the public that it’s protecting them from misbranded and unapproved drugs. Those designations sound scary and who would want such drugs? Well, Americans would. The fact is, whatever the FDA wants to call them, if medications are lawfully-produced under Good Manufacturing Practices, properly dispensed by a licensed professional and shipped by mail order, Americans are interested.
Oh, and these drugs are a hell of a lot cheaper.
Despite the clear advantages, these medications deemed to be misbranded or unapproved under U.S. law can be refused import by the FDA even if they are equally as safe and effective or the exact same as the medications sold in the U.S.
Here’s why… (more…)
Tagged with: adulterated, counterfeit, deflazacort, emflaza, FDA, marathon, misbranded, unapproved
The hearings on Capitol Hill about drug prices were a big deal this week. To policy wonks. All the rage was the report by the National Academies of Sciences about policies to lower drug prices. There was lot of intriguing discussion, debate, and deliberation on things we should do. Many that I agree with! Blah, blah, blah, blah. Medicare should negotiate drug prices! We should make generics available quicker! We should clamp down on patent abuse by big pharma! More price transparency! Stop direct-to-consumer advertising! Blah, blah, blah…blah. All of this was a big deal. To policy wonks.
What about people today?!??!
Now I like talking policy – too much sometimes. But I’m not writing about that hearing. No way. I came across a little piece in the New York Times, which loudly reminded me of this fact: While Congress debates, activists act, and policy nuts pontificate on drug prices –foreign pharmacies are the solution that saves American lives NOW. This is indisputable.
Access to more affordable drugs keeps Americans out of the hospital, able to lead more productive lives – and living. That’s what the most conclusive research proves.
For that reason: There’s no doubt in my mind that properly verified Canadian and other foreign online pharmacies are a boon to public health because they are far cheaper than U.S. pharmacies. Just to be clear: It’s not just that they help Americans save hundreds of millions of dollars a year – maybe billions (wish I knew). They are saving lives. (more…)
Tagged with: Commonwealth Fund, Congress, FDA, Hearings, Medication Adherence, National Academy of Sciences
The verdict is in: blister packs may be a safer bet for packaging your medication. In the U.S. and sometimes in Canada, however, medications are dispensed as loose pills.
According to the FDA, over 1.3 million people are injured each year due to medication mistakes, which include dispensing errors in U.S. hospitals and pharmacies. As discussed in a blogpost by Roger Bate, an economist at the American Enterprise Institute, it may be safer to receive your medications in blister packs, whether dispensed locally or from an international pharmacy by mail, and the FDA seems to agree.
Tagged with: Blister Packs, FDA, Roger Bate